These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 20415898)

  • 21. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
    Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials.
    Schnitzler MA; Lentine KL; Axelrod D; Gheorghian A; You M; Kalsekar A; L'Italien G
    Transplantation; 2012 Jan; 93(2):172-81. PubMed ID: 22198496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belatacept: in adult kidney transplant recipients.
    Garnock-Jones KP
    BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
    Martin ST; Powell JT; Patel M; Tsapepas D
    Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should belatacept be the centrepiece of renal transplantation?
    Huber M; Kemmner S; Renders L; Heemann U
    Nephrol Dial Transplant; 2016 Dec; 31(12):1995-2002. PubMed ID: 27288461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
    Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
    BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.
    Grinyo J; Alberu J; Contieri FL; Manfro RC; Mondragon G; Nainan G; Rial Mdel C; Steinberg S; Vincenti F; Dong Y; Thomas D; Kamar N
    Transpl Int; 2012 Oct; 25(10):1059-64. PubMed ID: 22816557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costimulation blockade with belatacept in renal transplantation.
    Vincenti F; Larsen C; Durrbach A; Wekerle T; Nashan B; Blancho G; Lang P; Grinyo J; Halloran PF; Solez K; Hagerty D; Levy E; Zhou W; Natarajan K; Charpentier B;
    N Engl J Med; 2005 Aug; 353(8):770-81. PubMed ID: 16120857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Belatacept in kidney transplantation.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
    Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
    Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
    Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Belatacept and Long-Term Outcomes in Kidney Transplantation.
    Vincenti F; Rostaing L; Grinyo J; Rice K; Steinberg S; Gaite L; Moal MC; Mondragon-Ramirez GA; Kothari J; Polinsky MS; Meier-Kriesche HU; Munier S; Larsen CP
    N Engl J Med; 2016 Jan; 374(4):333-43. PubMed ID: 26816011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
    Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
    Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
    Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
    Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
    Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.